免疫子制药(IMRN) 最新动态_F10_同花顺金融服务网

最新动态

每股收益： -0.01澳大利亚元 [[[0,"-0.0091"],[1,"-0.03"],[2,"-0.01"],[3,"-0.02"],[4,"-0.0070"]],[[0,"2024\u4e2d\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e2d\u62a5"],[3,"2025\u5e74\u62a5"],[4,"2026\u4e2d\u62a5"]],"\u6fb3\u5927\u5229\u4e9a\u5143"] 每股收益单位：澳大利亚元查看明细>>	归母净利润： -191.91万澳大利亚元同比增长22.89% [[[0,"-207.32"],[1,"-693.70"],[2,"-248.88"],[3,"-521.60"],[4,"-191.91"]],[[0,"2024\u4e2d\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e2d\u62a5"],[3,"2025\u5e74\u62a5"],[4,"2026\u4e2d\u62a5"]],"\u4e07\u6fb3\u5927\u5229\u4e9a\u5143"] 净利润单位：万澳大利亚元查看明细>>	每股净资产： 0.04澳大利亚元 [[[0,"0.08"],[1,"0.06"],[2,"0.05"],[3,"0.03"],[4,"0.04"]],[[0,"2024\u4e2d\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e2d\u62a5"],[3,"2025\u5e74\u62a5"],[4,"2026\u4e2d\u62a5"]],"\u6fb3\u5927\u5229\u4e9a\u5143"] 每股净资产单位：澳大利亚元查看明细>>	净资产收益率ROE(平均)： -18.15% [[[0,"-21.60"],[1,"-50.21"],[2,"-18.15"]],[[0,"2025\u4e2d\u62a5"],[1,"2025\u5e74\u62a5"],[2,"2026\u4e2d\u62a5"]],""] 总资产报酬率(ROE) 单位：% 查看明细>>
稀释每股收益： -0.01澳大利亚元 [[[0,"-0.0091"],[1,"-0.03"],[2,"-0.01"],[3,"-0.02"],[4,"-0.0070"]],[[0,"2024\u4e2d\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e2d\u62a5"],[3,"2025\u5e74\u62a5"],[4,"2026\u4e2d\u62a5"]],"\u6fb3\u5927\u5229\u4e9a\u5143"] 稀释每股收益单位：澳大利亚元查看明细>>	营业收入： 418.44万澳大利亚元同比增长4.76% [[[0,"235.56"],[1,"490.29"],[2,"399.43"],[3,"728.70"],[4,"418.44"]],[[0,"2024\u4e2d\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e2d\u62a5"],[3,"2025\u5e74\u62a5"],[4,"2026\u4e2d\u62a5"]],"\u4e07\u6fb3\u5927\u5229\u4e9a\u5143"] 营业收入单位：万澳大利亚元查看明细>>	每股现金流： -0.01澳大利亚元 [[[0,"-0.0088"],[1,"-0.03"],[2,"-0.02"],[3,"-0.03"],[4,"-0.0078"]],[[0,"2024\u4e2d\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e2d\u62a5"],[3,"2025\u5e74\u62a5"],[4,"2026\u4e2d\u62a5"]],"\u6fb3\u5927\u5229\u4e9a\u5143"] 每股现金流单位：澳大利亚元查看明细>>	总资产收益率(ROA)： -15.19% [[[0,"-17.96"],[1,"-40.62"],[2,"-15.19"]],[[0,"2025\u4e2d\u62a5"],[1,"2025\u5e74\u62a5"],[2,"2026\u4e2d\u62a5"]],""] 总资产收益率(ROA) 单位：% 查看明细>>

注释：公司货币计价单位为澳大利亚元

近期重要事件

2026-03-02	详情>> 股本变动：变动后总股本816.63万股变动原因 ▼▲ 原因： From July 1, 2025 to December 31, 2025 Issue at US$1.8939 pursuant to At the Market facility (2025-07-17) Issue at US$1.8782 pursuant to At the Market facility (2025-07-18) Issue at US$2.1374 pursuant to At the Market facility (2025-07-21) Issue at US$2.3008 pursuant to At the Market facility (2025-10-20) Issue at US$1.9631 pursuant to At the Market facility (2025-11-07) Issue at US$2.0809 pursuant to At the Market facility (2025-12-05)
2026-03-02	详情>> 业绩披露： 2026年中报每股收益-0.01澳大利亚元,归母净利润-191.91万澳大利亚元,同比去年增长22.89%
2025-09-25	详情>> 业绩披露： 2025年年报每股收益-0.02澳大利亚元,归母净利润-521.6万澳大利亚元,同比去年增长24.81%
2025-02-28	详情>> 业绩披露： 2025年中报每股收益-0.01澳大利亚元,归母净利润-248.88万澳大利亚元,同比去年增长-20.05%
2024-10-03	复牌提示： 2024-10-02 19:05:25 停牌，复牌日期 2024-10-04 07:50:00
2024-10-01	详情>> 业绩披露： 2024年年报每股收益-0.03澳大利亚元,归母净利润-693.7万澳大利亚元,同比去年增长-83.2%
2024-02-28	详情>> 业绩披露： 2024年中报每股收益-0.01澳大利亚元,归母净利润-207.32万澳大利亚元,同比去年增长-4.79%
2023-10-23	股东大会：将于2023-11-21召开股东大会会议内容 ▼▲ 1.Adoption of Remuneration Report 2.Re-election of Dr Roger Aston 3.Approval of increased placement capacity 4.Approval to Amend Constitution - Employee share scheme provisions 5.Approval of Omnibus Incentive Plan 6.Approval of the Issue of Options to Mr Paul Brennan
2023-09-28	详情>> 业绩披露： 2023年年报每股收益-0.02澳大利亚元,归母净利润-378.65万澳大利亚元,同比去年增长-32.66%
2023-09-28	详情>> 业绩披露： 2021年年报每股收益-0.04澳大利亚元,归母净利润-838.45万澳大利亚元,同比去年增长-186.43%
2023-02-28	详情>> 业绩披露： 2023年中报每股收益-0.01澳大利亚元,归母净利润-197.84万澳大利亚元,同比去年增长-9.22%
2022-10-21	股东大会：将于2022-11-21召开股东大会会议内容 ▼▲ 1.Adoption of Remuneration Report. 2.Re-election of Mr Stephen Anastasiou. 3.Re-election of Prof. Ravi Savarirayan. 4.Election of Mr Paul Brennan. 5.Approval of increased placement capacity. 6.Approval to Amend Constitution - virtual meetings. 7.Approval to Amend Constitution - re-insert Proportional Bid Provisions.
2022-09-09	详情>> 业绩披露： 2022年年报每股收益-0.01澳大利亚元,归母净利润-285.43万澳大利亚元,同比去年增长65.96%
2022-09-09	详情>> 业绩披露： 2020年年报每股收益-0.02澳大利亚元,归母净利润-292.72万澳大利亚元,同比去年增长37.14%
2022-02-25	详情>> 业绩披露： 2022年中报每股收益-0.01澳大利亚元,归母净利润-181.15万澳大利亚元,同比去年增长68.43%
2021-11-16	股东大会：将于2021-12-15召开股东大会会议内容 ▼▲ 1.Adoption of Remuneration Report 2.Re-election of Mr Daniel Pollock 3.Approval of increased placement capacity 4.Issue of 218,750 Shares to Grandlodge Pty Ltd or its nominee 5.Approval of Omnibus Incentive Plan
2021-09-06	温馨提示：美股因劳工节，9月6日休市一天
2020-09-28	股东大会：将于2020-10-29召开股东大会会议内容 ▼▲ 1.NON-BINDING RESOLUTION TO ADOPT REMUNERATION REPORT 2.RE-ELECTION OF DR ROGER ASTON AS A DIRECTOR 3.RATIFICATION OF PRIOR ISSUE OF SHARES - PUBLIC OFFERING OF ADSs 4.APPROVAL TO REFRESH EXECUTIVE SHARE OPTION PLAN 5.ADOPTION OF NON-EXECUTIVE DIRECTOR REMUNERATION POOL 6.APPROVAL TO ISSUE SHARES TO A DIRECTOR – DR ROGER ASTON 6.2APPROVAL TO ISSUE SHARES TO A DIRECTOR – MR DANIEL POLLOCK 6.3APPROVAL TO ISSUE SHARES TO A DIRECTOR – PROF. RAVI SAVARIRAYAN 6.4APPROVAL TO ISSUE SHARES TO A DIRECTOR – MR STEPHEN ANASTASIOU 6.5APPROVAL TO ISSUE SHARES TO A DIRECTOR – MR PETER ANASTASIOU 7.APPROVAL TO ISSUE OPTIONS TO DR ROGER ASTON 7.2APPROVAL TO ISSUE OPTIONS TO MR DANIEL POLLOCK 7.3APPROVAL TO ISSUE OPTIONS TO PROF. RAVI SAVARIRAYAN 7.4APPROVAL TO ISSUE OPTIONS TO MR STEPHEN ANASTASIOU 7.5APPROVAL TO ISSUE OPTIONS TO MR PETER ANASTASIOU 8.APPROVAL OF 10% PLACEMENT FACILITY
2019-10-04	股东大会：将于2019-11-06召开股东大会会议内容 ▼▲ 1.Non-binding resolution to adopt Remuneration Report 2.ARe-election of Mr Stephen Anastasiou as a Director 2.BRe-election of Prof. Ravi Savarirayan as a Director 3.Approval to issue Options to a Director - Dr Gary S. Jacob 4.Ratification of prior issue of Shares 5.Ratification of prior issue of Shares 6.Approval of Placement Facility 7.Approve the issue of Shares to a Related Party – Grandlodge Pty Ltd or its nominee

主营业务分析

注：通常在中报、年报时披露　

项目名称		营业收入(万澳大利亚元)	收入比例(%)
按业务	超免疫产品	418.4357	100.00
按地区	澳大利亚	327.3695	78.24
	美国	85.4737	20.43
	加拿大	5.5925	1.34

项目名称		营业收入(万澳大利亚元)	收入比例(%)
按业务	超免疫产品	728.7002	100.00
按地区	澳大利亚	524.996	72.05
	美国	165.8336	22.76
	加拿大	37.8706	5.20

项目名称		营业收入(万澳大利亚元)	收入比例(%)
按业务	超免疫产品	399.4341	100.00
按地区	澳大利亚	288.6722	72.27
	美国	73.1213	18.31
	加拿大	37.6406	9.42

公司新闻

热点新闻更多>>

公司公告更多>>

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。